Human immunodeficiency virus and the outcome of treatment for new and recurrent pulmonary tuberculosis in African patients.
about
Prisoners co-infected with tuberculosis and HIV: a systematic reviewEarly outcomes of MDR-TB treatment in a high HIV-prevalence setting in Southern AfricaIncidence and risk factors of serious adverse events during antituberculous treatment in Rwanda: a prospective cohort studyAmbulatory multi-drug resistant tuberculosis treatment outcomes in a cohort of HIV-infected patients in a slum setting in Mumbai, IndiaRe-treatment tuberculosis cases categorised as "other": are they properly managed?Survival of civilian and prisoner drug-sensitive, multi- and extensive drug- resistant tuberculosis cohorts prospectively followed in RussiaImpact of DOTS expansion on tuberculosis related outcomes and costs in HaitiCost-effectiveness of novel vaccines for tuberculosis control: a decision analysis study.Is HIV-associated tuberculosis a risk factor for the development of cryptococcal disease?The changing epidemiology of tuberculosis in a Spanish tertiary hospital (1995-2013)Outcomes in HIV-infected adults with tuberculosis at clinics with and without co-located HIV clinics in Botswana.Molecular epidemiology study of exogenous reinfection in an area with a low incidence of tuberculosisMycobacterium tuberculosis microbiologic and clinical treatment outcomes in a randomized trial of immediate versus CD4(+)-initiated antiretroviral therapy in HIV-infected adults with a high CD4(+) cell count.Treatment of HIV-related tuberculosis in the era of effective antiretroviral therapy.Tuberculosis and HIV infection: epidemiology, immunology, and treatment.Time of highest tuberculosis death risk and associated factors: an observation of 12 years in Northern ThailandTiming, rates, and causes of death in a large South African tuberculosis programme.A meta-analysis of drug resistant tuberculosis in Sub-Saharan Africa: how strongly associated with previous treatment and HIV co-infection?Diabetes and risk of tuberculosis relapse: nationwide nested case-control study.Tuberculosis and HIV disease: two decades of a dual epidemic.Prevalence and drug resistance profile of Mycobacterium tuberculosis isolated from pulmonary tuberculosis patients attending two public hospitals in East Gojjam zone, northwest Ethiopia.Decreased expression of T-cell costimulatory molecule CD28 on CD4 and CD8 T cells of mexican patients with pulmonary tuberculosisIndependent predictors of tuberculosis mortality in a high HIV prevalence setting: a retrospective cohort study.Efficacy of an unsupervised 8-month rifampicin-containing regimen for the treatment of pulmonary tuberculosis in HIV-infected adults. Uganda-Case Western Reserve University Research Collaboration.HIV-associated tuberculosis and cryptococcosis in resource-limited settings.The Effect of Low CD4+ Lymphocyte Count on the Radiographic Patterns of HIV Patients with Pulmonary Tuberculosis among NigeriansPredictors of mortality in patients initiating antiretroviral therapy in Durban, South Africa.When to start antiretroviral therapy during tuberculosis treatment?The value of initial cavitation to predict re-treatment with pulmonary tuberculosis.Factors associated with recurrent tuberculosis more than 12 months after treatment completion.Pretreatment neutrophil-to-lymphocyte ratio in peripheral blood was associated with pulmonary tuberculosis retreatment.An updated systematic review and meta-analysis on the treatment of active tuberculosis in patients with HIV infection.Morbidity and mortality in South African gold miners: impact of untreated disease due to human immunodeficiency virus.Endogenous reactivation and true treatment failure as causes of recurrent tuberculosis in a high incidence setting with a low HIV infection.Exogenous reinfection of tuberculosis in a low-burden area.Rare Association of Severe Cryptococcal and Tuberculosis in Central Nervous System in a case of SarcoidosisTrends in prevalence of multi drug resistant tuberculosis in sub-Saharan Africa: A systematic review and meta-analysis.Management of co-infection with HIV and TB.HIV Treatment in Developing Countries.Occupational lung disease in the South African mining industry: research and policy implementation.
P2860
Q28080180-493BD2B9-8623-40E3-8238-5ACFC5F580E1Q28476241-BEB85985-54E5-4A44-94AC-822C0B025BFEQ28478173-2A7B4458-7190-4B41-8A6D-DE78820805F7Q28478204-CC45B2FA-1A20-487D-82B5-311A73DC3ED3Q28478395-15C64283-C0A9-4208-86FA-5B3FFFE4A00AQ28478528-8B0E9BA5-B339-4627-93E7-C4E93593D96DQ33254073-34330538-C889-4B7B-86AA-DA49EA14AAA0Q33804506-76B56058-012A-4036-B96A-4B028E9F0A51Q33854505-2D19C429-C66C-4F7A-A44D-F76F2881E60AQ33879669-047D1972-70F8-4373-AC13-BA1C4D7BE5D9Q33922724-F2CDFC73-AB99-4943-BB9E-236D25E0B481Q33972593-271F0D82-8266-492D-806F-CDCCB5FBE943Q34056936-3E8DB93A-5AAC-449E-9B81-2BCA1A4C44BFQ34297893-20FDE774-D98D-4D2E-8419-6DFE1CEAF8EBQ34394728-EAEBD594-2F0C-4578-BCAD-57777F6CCA01Q34748321-FADBA964-38FF-4DF9-8BE1-C11310B90EFEQ34979324-4C085BE0-F691-4584-B125-F8FDEC7F71C1Q35059462-1448844A-F1FF-4C47-A442-9ABD91F16738Q35129306-42D7D0E8-C578-4A50-B671-7555F6A9295BQ35598500-DA905940-606F-4F46-B1C3-7859DF177A75Q35669319-F137100F-8ABA-475C-B564-96137865BB1AQ35910449-69A12E34-4B73-4637-8CE3-B6D61918E7ADQ36131547-A93E1994-10A4-4683-803B-A9410CE54499Q36165307-44114816-A745-4626-87B6-14872A2B7680Q36223899-4ED303E5-1A47-4695-87A7-1448BB619B7DQ36605934-FEC15BB5-74E9-4ECB-9154-E4B79539782DQ36692375-52D6A741-9288-4936-876C-344F3E31DC19Q36739450-5B19F8AA-DA57-40D8-91BA-5E9B643C14F6Q36875856-E4E75BF2-A028-465C-B60A-E9A01EAAC868Q37371468-07265483-7284-431F-A88C-C518D84576EBQ37675562-905FCEDD-4D60-4ED9-A8C9-C9578DA56404Q38028326-770AEC44-3326-4116-B92F-41716BC4FD57Q38953092-A93DE06C-BF7E-46E8-AF0D-BA2D9DD37DE1Q39450961-E9DA1D7D-151A-4515-8A54-F87ACA5C8335Q41441140-8B142CC3-498A-477A-9E03-01C8F6461093Q41728327-E4A1520A-62E4-40C7-AEB8-4102C3A8F9E1Q41930740-83DB453F-79B1-45DD-AB4B-E0C853ABB289Q42776942-514C13A3-2FE9-4B06-BEA9-3C4F53F820BAQ46472427-FEB1F278-D2DA-45FA-94A9-B8F0420C7BC6Q46532712-939B9A01-2196-4142-A640-39B7D1AA2B6B
P2860
Human immunodeficiency virus and the outcome of treatment for new and recurrent pulmonary tuberculosis in African patients.
description
1999 nî lūn-bûn
@nan
1999年の論文
@ja
1999年学术文章
@wuu
1999年学术文章
@zh
1999年学术文章
@zh-cn
1999年学术文章
@zh-hans
1999年学术文章
@zh-my
1999年学术文章
@zh-sg
1999年學術文章
@yue
1999年學術文章
@zh-hant
name
Human immunodeficiency virus a ...... erculosis in African patients.
@en
Human immunodeficiency virus a ...... erculosis in African patients.
@nl
type
label
Human immunodeficiency virus a ...... erculosis in African patients.
@en
Human immunodeficiency virus a ...... erculosis in African patients.
@nl
prefLabel
Human immunodeficiency virus a ...... erculosis in African patients.
@en
Human immunodeficiency virus a ...... erculosis in African patients.
@nl
P2093
P2860
P1476
Human immunodeficiency virus a ...... berculosis in African patients
@en
P2093
Godfrey-Faussett P
Shearer SC
P2860
P304
P356
10.1164/AJRCCM.159.3.9804147
P407
P577
1999-03-01T00:00:00Z